Volume 31, Issue 204 (1-2022)
J Mazandaran Univ Med Sci 2022, 31(204): 151-156 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sahebnasagh A, Basiratian A, Zahmatkesh A, Hajimaghsoudi M, Saghafi F. Investigating the Use of Pantoprazole in Yazd Shahid Rahnemoon Hospital, 2019. J Mazandaran Univ Med Sci 2022; 31 (204) :151-156
URL: http://jmums.mazums.ac.ir/article-1-16871-en.html
URL: http://jmums.mazums.ac.ir/article-1-16871-en.html
Adeleh Sahebnasagh 
, Ali Basiratian , Amirhossein Zahmatkesh , Majid Hajimaghsoudi , Fatemeh Saghafi
, Ali Basiratian , Amirhossein Zahmatkesh , Majid Hajimaghsoudi , Fatemeh Saghafi
Abstract: (1301 Views)
Background and purpose: Proton pump inhibitors (PPIs) are one of the main therapeutic agents for acid-related diseases. Pantoprazole, with minimal drug interaction, is one of the well-known PPIs. According to various studies, 25-75% of pantoprazole injections have no indications and cause a high burden on health systems. The aim of this study was to investigate the indication and rate of pantoprazole injections in Yazd Rahnemoon Hospital, Iran.
Materials and methods: This cross-sectional study was performed in 72 hospitalized patients in invasive care units, and internal and emergency wards between March and December 2019. Demographic and clinical data, risk factors, PPI indication, and doses of utilized pantoprazole were recorded. The rationality of pantoprazole prescription was confirmed by comparing the drug information from up-to-date database under the supervision of a clinical pharmacist in the hospital.
Results: In total, out of 60 patients who received IV pantoprazole, 52.8% could have received the oral form and in 69.4% there was no indication to use IV pantoprazole.
Conclusion: In this study, parenteral form of pantoprazole was not indicated in majority of the patients. Guidelines should be approved to prevent irrational administration of parental PPIs in hospitals.
Materials and methods: This cross-sectional study was performed in 72 hospitalized patients in invasive care units, and internal and emergency wards between March and December 2019. Demographic and clinical data, risk factors, PPI indication, and doses of utilized pantoprazole were recorded. The rationality of pantoprazole prescription was confirmed by comparing the drug information from up-to-date database under the supervision of a clinical pharmacist in the hospital.
Results: In total, out of 60 patients who received IV pantoprazole, 52.8% could have received the oral form and in 69.4% there was no indication to use IV pantoprazole.
Conclusion: In this study, parenteral form of pantoprazole was not indicated in majority of the patients. Guidelines should be approved to prevent irrational administration of parental PPIs in hospitals.
Type of Study: Brief Report |
Subject:
Clinical pharmacy
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
